BARNETT INTERNATIONAL ENTERS ACCREDITED COLLABORATION WITH FW PHARMA SYSTEMS LTD.

PHILADELPHIA, PA, September 24, 2002 — Barnett International (Barnett), a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), has entered into an accredited collaboration with FW Pharma Systems Ltd., developer of the IMPACT (TM) clinical trials management system. IMPACT (International Management Package for the Administration of Clinical Trials) is a market leader in clinical trials management systems for the pharmaceutical and biotechnology industries. Barnett International is headquartered in Media, PA, and FW Pharma Systems is headquartered in Birmingham, UK.

Under the terms of the collaboration, Barnett will develop a series of Web/Computer Based Training (WBT/CBT) modules to provide IMPACT users with e-learning options to complement traditional instructor-led training. In addition, Barnett will have access to early customer releases of major IMPACT upgrades to prepare implementation services prior to general customer release.

"This collaboration recognizes Barnett's experience with global deployment of IMPACT, as well as Barnett's considerable knowledge of clinical trial processes and leading-edge training solutions," said James H. Geddes, President of Barnett International

Paul Tebbs, Business Development Director of FW Pharma Systems, added, "We have 30 IMPACT customers with 13,000 licensed users ranging from those in the top 20 pharmaceutical companies in the world to biotechnology companies on the West Coast. Barnett will be able to leverage their considerable experience to allow the customer to maximize the benefits of IMPACT from the start."

Barnett International is a subsidiary of PAREXEL International Corporation, one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its newest subsidiary, Perceptive Informatics, Inc., provides a variety of technology products and services, including web-based portal solutions and voice and data systems, which are designed to accelerate and enhance the clinical development and launch processes. The Company’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 56 locations throughout 37 countries around the world, and has approximately 4,930 employees.

This release contains "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears", “estimates”, “projects” and similar expressions are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the cancellation, revision, or delay of contracts, including those contracts in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic and political risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Form 10-Q for the period ended March 31, 2002, as filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company disclaims any duty to update any of the forward-looking statements contained in this press release.

IMPACT (TM) is a registered trademark of FW Pharma Systems Ltd.